SCHEMBL10142489

SCHEMBL10142489

c1cc2c(cn1)CCc1cc[nH]c1-2

nearest known ligand 0.41

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CHRNB2 P17787 2/20 0.41
CHRNA4 P43681 2/20 0.41
SIGMAR1 Q99720 1/20 0.41
NUDT1 P36639 2/20 0.37
IGF1R P08069 1/20 0.34
CDK2 P24941 1/20 0.34
DYRK1B Q9Y463 1/20 0.34
PRKCI P41743 1/20 0.33
MAPK14 Q16539 2/20 0.33
GCGR P47871 1/20 0.33
PDE3B Q13370 1/20 0.31
PDE3A Q14432 1/20 0.31
NFATC1 O95644 2/20 0.31
GSK3B P49841 2/20 0.31
DYRK1A Q13627 2/20 0.31
HSP90AA1 P07900 1/20 0.31
MAP2K1 Q02750 1/20 0.31
MAOA P21397 1/20 0.31
MAOB P27338 1/20 0.31
ROCK2 O75116 1/20 0.30

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2993394 0.78 CHRNB2 (0.39) CHRNB2CHRNA4SIGMAR1NUDT1IGF1R
SCHEMBL10142493 0.74 CHRNB2 (0.36) CHRNB2CHRNA4SIGMAR1CDK2DYRK1B
SCHEMBL22579806 0.73 SIGMAR1 (0.48) CHRNB2CHRNA4SIGMAR1PDE3BPDE3A
SCHEMBL10142500 0.72 GCGR (0.39) CHRNB2CHRNA4SIGMAR1MAPK14GCGR
SCHEMBL2257675 0.71 CES1 (0.48) DYRK1BDYRK1AMAP2K1MAOAMAOB
SCHEMBL7431568 0.70 PDE3B (0.36) CHRNB2CHRNA4SIGMAR1CDK2DYRK1B
SCHEMBL3597400 0.70 KDM4C (0.38) CHRNB2CHRNA4ROCK2
SCHEMBL29792666 0.69 CYP1A2 (0.53) CHRNB2CHRNA4SIGMAR1PDE3BPDE3A
SCHEMBL4323285 0.69 CYP1A2 (0.53) CHRNB2CHRNA4SIGMAR1PDE3BPDE3A
SCHEMBL10142566 0.69 CHRNB2 (0.35) CHRNB2CHRNA4SIGMAR1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8207180-B2 Tricyclic indoles and (4,5-dihydro) indoles NERVIANO MEDICAL SCIENCES S.R.L. (IT) 2012-06-26 US disclosed
US-8207180-B2 Tricyclic indoles and (4,5-dihydro) indoles NERVIANO MEDICAL SCIENCES S.R.L. (IT) 2012-06-26 US disclosed
US-20100075998-A1 TRICYCLIC INDOLES AND (4,5-DIHYDRO) INDOLES NERVIANO MEDICAL SCIENCES S.R.L. (IT) 2010-03-25 US disclosed
US-20100075998-A1 TRICYCLIC INDOLES AND (4,5-DIHYDRO) INDOLES NERVIANO MEDICAL SCIENCES S.R.L. (IT) 2010-03-25 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100075998-A1 TRICYCLIC INDOLES AND (4,5-DIHYDRO) INDOLES CDC7, CDK7, CDK17 CHRNB2 3708/4885CHRNA4 3010/4885SIGMAR1 2491/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.